Background: Cholinesterase inhibitors represent three of the four treatments for Alzheimer's
disease (AD), and target the pathological reduction of acetylcholine levels. Here we aimed …

Scientific evidence collected over the past 4 decades suggests that a loss of cholinergic
innervation in the cerebral cortex of patients with Alzheimer's disease is an early pathogenic …

Cognitive deficits in neuropsychiatric disorders, such as Alzheimer's disease (AD), have
been closely related to cholinergic deficits. We have compared different markers of …

Although the neurodegeneration occurring in Alzheimer's disease (AD) affects multiple
neurotransmitters, the cholinergic system has received the greatest attention. Acetylcholine …

The neuropathological hallmarks of Alzheimer s disease (AD) are the presence of senile
(neuritic) plaques (NP), neurofibrillary tangles (NFT), synapse loss, and neuronal cell loss …

INTRODUCTION Alzheimer disease (AD) is a neurodegenerative disease affecting between
Solo and 10% of the population (1) over the age of 65. Individuals with AD exhibit profound …

It is currently unclear whether impairment of the cholinergic system is present in Alzheimer
disease (AD) already at an early stage and to what extent it depends on degeneration of the …

One characteristic neuropathological feature of Alzheimer's disease (AD) is profound
neuronal loss in the nucleus basalis of Meynert, the major source of cholinergic innervation …

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by
cognitive decline associated with a deficit in cholinergic function. Inhibitors of …

Objective: to examine the effect of medications with anticholinergic effects on cognitive
impairment and deterioration in Alzheimer's dementia (AD). Methods: cognitive function was …